Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Flutiform

- PMLiVE

Novartis highlights potential of its radioligand therapy in prostate cancer at ASCO

mCRPC patients treated with Lu-PSMA-617 plus best standard of care achieved a 38% reduction in the risk of death

- PMLiVE

Novartis’ Kisqali shows long-term improvements in breast cancer patients

Data shows the ‘longest median overall survival in postmenopausal HR+/HER2- metastatic breast cancer patients’

- PMLiVE

First NHS patient treated with Novartis’ SMA gene therapy Zolgensma

Novartis and NHS England reached a landmark deal for the gene therapy earlier this year

- PMLiVE

GSK, Vir’s COVID-19 mAb scores FDA emergency use approval

Interim phase 3 trial results found sotrovimab reduced the risk of hospitalisation or death by 85% compared to placebo

The Future of Digital Pills

Valerie Sullivan, President and CEO at etectRx, dives into digital pills in healthcare and clinical research. Among many other things, we discuss how Pharma companies can benefit from the ability...

Impetus Digital

- PMLiVE

Sanofi, GSK begin enrolment for phase 3 COVID-19 vaccine study

Study will investigate two formulations targeting the Wuhan strain and the South African variant

- PMLiVE

Novartis, Molecular Partners launch global study of novel COVID-19 drug

Initial positive phase 1 study results found that the drug was safe and well tolerated, with no significant adverse events reported

- PMLiVE

UK government ‘concerned’ over Elliott Management’s plans for GSK

'Activist' hedge fund Elliott Management has built up a sizeable stake in the British drugmaker

- PMLiVE

BeiGene, Novartis’ tislelizumab report promising topline results in nasopharyngeal cancer

In 2018, 46.9% of global cases of nasopharyngeal cancer occurred in China

- PMLiVE

Sandoz reveals antibiotic manufacturing expansion plans in Europe

Builds on company's previous commitments to drive the long-term future of integrated antibiotics manufacturing in Europe

- PMLiVE

GSK and Medicago’s COVID-19 vaccine shows promising antibody responses in phase 2

Neutralising antibody responses in vaccinated participants were about ten times higher than those seen in a panel of sera from recovering COVID-19 patients

- PMLiVE

US Supreme Court rebuffs Sandoz’s Enbrel biosimilar patent case

Amgen will retain market exclusivity on blockbuster arthritis drug until 2029

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links